GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Accumulated other comprehensive income (loss)

Arovella Therapeutics (FRA:E4NA) Accumulated other comprehensive income (loss) : €1.29 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Arovella Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was €1.29 Mil.

Arovella Therapeutics's quarterly Accumulated other comprehensive income (loss) increased from Dec. 2022 (€0.91 Mil) to Jun. 2023 (€1.22 Mil) and increased from Jun. 2023 (€1.22 Mil) to Dec. 2023 (€1.29 Mil).

Arovella Therapeutics's annual Accumulated other comprehensive income (loss) increased from Jun. 2021 (€0.29 Mil) to Jun. 2022 (€0.74 Mil) and increased from Jun. 2022 (€0.74 Mil) to Jun. 2023 (€1.22 Mil).

Arovella Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Arovella Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Accumulated other comprehensive income (loss) Chart

Arovella Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.42 1.00 0.29 0.74 1.22

Arovella Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.74 0.91 1.22 1.29

Arovella Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Arovella Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics (FRA:E4NA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
ASX:RCE ASX:PIQ ASX:PAR ASX:AGN ASX:OCC ASX:PAA ASX:ACW ASX:DXB ASX:LTP ASX:ADO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ALA:Australia
Address
62 Lygon Street, Level 3, Carlton, WA, AUS, 3053
Website
https://www.arovella.com
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (FRA:E4NA) Headlines

No Headlines